Press Releases | BioSenic

BioSenic provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Read more about BioSenic provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Transparency notification received from S.R.I.W. SA and Sofipôle SA

Read more about Transparency notification received from S.R.I.W. SA and Sofipôle SA

Information on the total number of voting rights and shares

Read more about Information on the total number of voting rights and shares

Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation

Read more about Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation

Bone Therapeutics provides Third Quarter 2022 Business Update

Read more about Bone Therapeutics provides Third Quarter 2022 Business Update

Transparency notification received from S.F.P.I/F.P.I.M

Read more about Transparency notification received from S.F.P.I/F.P.I.M

Bone Therapeutics to regain worldwide rights to ALLOB

Read more about Bone Therapeutics to regain worldwide rights to ALLOB

Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022

Read more about Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022

Bone Therapeutics: Information on the total number of voting rights and shares

Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Transparency notification received from CPH Banque

Read more about Transparency notification received from CPH Banque

Subscribe to Press Releases